REVELATION BIOSC -CW27 (REVBW) Stock News

USA - NASDAQ:REVBW -

0.0095 USD

0 (0%)

Last: 11/7/2025, 8:13:59 PM

Technical Analysis

REVBW Latest News, Press Relases and Analysis

All

Press Releases

5 months ago - By: Yahoo Finance - Mentions: USFD SCVL NVDA CRM ...

US Foods Seeing Inflows

5 months ago - By: Yahoo Finance - Mentions: REVB 1456 URBN KSS ...

S&P lowers outlook on Volvo Cars rating citing US tariffs, competition in China

5 months ago - By: Yahoo Finance - Mentions: URBN 1456

Urban Outfitters Seeing Inflows

5 months ago - By: Yahoo Finance - Mentions: 1456 URBN KSS

Iron ore pessimism subsides despite looming Simandou supply

5 months ago - By: Yahoo Finance - Mentions: 1456 URBN IBKR ZK

Morning Bid: Tariffs return along with capital tax fears

5 months ago - By: Yahoo Finance - Mentions: CADL PFE VREX CTKB ...

Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer

5 months ago - By: Yahoo Finance - Mentions: CTKB MS PFGC CRM ...

Cytek Biosciences, Inc. (CTKB) Elevates Cell Analysis with New Aurora Evo System

5 months ago - By: Yahoo Finance - Mentions: CRM INFA DELL DHI ...

Bernstein Raises Salesforce (CRM) Price Target to $255, Keeps Underperform Rating

5 months ago - By: Yahoo Finance - Mentions: REVB ESLT CTKB KROS ...

Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering

5 months ago - By: Yahoo Finance - Mentions: MS CRM INFA WFC ...

Morgan Stanley Lifts Salesforce, Inc. (CRM)’s Price Target to $404, Maintains Overweight Rating

5 months ago - By: Yahoo Finance - Mentions: ESLT CRM UNH DHI ...

Elbit Systems Ltd. (ESLT) Secures $330M in Naval Defense Contracts

5 months ago - By: Yahoo Finance - Mentions: VREX CTKB KROS CADL ...

Varex Imaging Corporation (VREX) Downgraded by S&P as Regulatory Outlook Remains Cloudy

7 months ago - By: Yahoo Finance - Mentions: REVB TSLA

Why Revelation Biosciences Inc. (REVB) Went Down On Thursday?

3 years ago - By: Revelation Biosciences, Inc. - Mentions: REVB

Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress

3 years ago - By: Revelation Biosciences, Inc. - Mentions: REVB

Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering

3 years ago - By: Revelation Biosciences, Inc. - Mentions: REVB

Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering

3 years ago - By: Revelation Biosciences, Inc. - Mentions: REVB

Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

3 years ago - By: Revelation Biosciences, Inc. - Mentions: REVB

Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

3 years ago - By: Revelation Biosciences, Inc. - Mentions: REVB

Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate Progress

4 years ago - By: Revelation Biosciences, Inc. - Mentions: REVB

Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate Update

4 years ago - By: Revelation Biosciences, Inc. - Mentions: REVB

Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza Infection

4 years ago - By: Revelation Biosciences, Inc. - Mentions: REVB

Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor Conference

4 years ago - By: Revelation Biosciences, Inc. - Mentions: REVB

Revelation Biosciences Raises $7.76 Million in Equity Financing

4 years ago - By: Revelation Biosciences, Inc. - Mentions: REVB

REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company